271 studies found for:    Open Studies | "Carcinoma, Renal Cell"
Show Display Options
Rank Status Study
21 Recruiting Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Conditions: Clear-cell Renal Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
22 Recruiting Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers
Conditions: Healthy, no Evidence of Disease;   Localized Transitional Cell Cancer of the Renal Pelvis and Ureter;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Bladder Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Uterine Sarcoma;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage II Bladder Cancer;   Stage II Renal Cell Cancer;   Stage II Urethral Cancer;   Stage IIA Cervical Cancer;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Cervical Cancer;   Stage IIB Colon Cancer;   Stage IIB Gastric Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Colon Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Bladder Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage III Urethral Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Cervical Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IV Urethral Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Cervical Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Stage IVB Uterine Sarcoma;   Ureter Cancer
Interventions: Other: educational intervention;   Behavioral: telephone-based intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
23 Recruiting Study of Kidney Tumors in Young Patients
Conditions: Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Renal Cell Cancer;   Stage I Wilms Tumor;   Stage II Renal Cell Cancer;   Stage II Wilms Tumor;   Stage III Renal Cell Cancer;   Stage III Wilms Tumor;   Stage IV Renal Cell Cancer;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions: Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
24 Not yet recruiting REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Intervention: Drug: Iodine (124I) Girentuximab
25 Unknown  microRNA Expression in Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention:
26 Recruiting Entinostat and Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: entinostat;   Biological: aldesleukin;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography
27 Recruiting Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery
Conditions: Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Radiation: stereotactic body radiation therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
28 Recruiting Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Conditions: Renal Cell Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: Nivolumab;   Biological: Pazopanib;   Drug: Sunitinib;   Biological: Ipilimumab
29 Recruiting Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Biological: bevacizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
30 Recruiting Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY 43-9006)
31 Not yet recruiting Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer
Condition: Carcinoma, Renal Cell
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
32 Recruiting Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Device: DCE-MRI and Quantitative Doppler Ultrasound
33 Recruiting Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Drug: MK-3475
34 Recruiting RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
Conditions: Carcinoma;   Renal Cell;   Non Clear Cell Renal Carcinoma;   Papillary Cell Renal Carcinoma;   Adenocarcinoma
Intervention: Drug: RAD001
35 Recruiting Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC
Conditions: Kidney Cancer;   Renal Cell Carcinoma;   Advanced Renal Cell Carcinoma
Intervention:
36 Recruiting Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib
37 Recruiting INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
Conditions: Carcinoma, Renal Cell;   Lymphoma, Mantle-Cell
Intervention: Other: Temsirolimus (Non-Interventional Study)
38 Recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Melanoma;   Recurrent Prostate Cancer;   Recurrent Renal Cell Cancer;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: hydroxychloroquine;   Other: pharmacological study;   Other: laboratory biomarker analysis
39 Recruiting Tumor Registry of Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention:
40 Recruiting Autoantibody Blood Test in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years